Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dexanabinol

Next Previous
X
Search
Drug Profile

Dexanabinol

Alternative Names: Dexanabinone; ETS-2101; HU-211; PA-50211; PRS-211007; Sinnabidol

Latest Information Update: 28 May 2018

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hebrew University of Jerusalem
  • Developer e-Therapeutics; Northern Institute for Cancer Research; Pharmos Corporation; University of California, San Diego
  • Class 3-ring heterocyclic compounds; Antineoplastics; Cannabinoids; Neuroprotectants; Small molecules
  • Mechanism of Action Apoptosis stimulants; NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Brain injuries
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Brain cancer; Malignant melanoma; Solid tumours
  • Discontinued Brain injuries; Glaucoma; Mild cognitive impairment; Multiple sclerosis

Most Recent Events

  • 28 May 2018 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, First-line therapy, Late-stage disease) in Germany (IV, Infusion)
  • 28 May 2018 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, First-line therapy, Late-stage disease) in Poland (IV, Infusion)
  • 28 May 2018 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, First-line therapy, Late-stage disease) in Spain (IV, Infusion)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top